Orchestra BioMed Holdings, Inc.
- Open
- 5.23
- Day high
- 5.33
- Day low
- 5.02
- Prev close
- 5.18
- Volume
- 277K
- Mkt cap
- $303M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 10.3
- P/S
- 9.5
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$115K over the last 3 months (1 open-market buy, 2 sales)
- 🏛Institutions reducing (13F)
Orchestra BioMed Holdings, Inc. (OBIO) is a Healthcare company listed on NASDAQ. The stock is up 87% over the past year. Over the trailing 3 months, insiders filed 1 open-market buy and 2 sales (SEC Form 4).
Orchestra BioMed Holdings, Inc. (OBIO) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
OBIO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $-0.39 | $-0.38 | +3.1% | $88000 | -36.1% |
| May 12, 2026 | $-0.40 | $-0.33 | +17.5% | $110000 | -88.0% |
| Mar 12, 2026 | $-0.38 | $0.26 | +168.8% | $31M | +3220.8% |
| Aug 12, 2025 | $-0.51 | $-0.50 | +2.0% | $836000 | +7.3% |
| Apr 2, 2025 | $-0.43 | $-0.43 | +0.0% | $253000 | -51.6% |
| Mar 26, 2025 | $-0.43 | $-0.37 | +14.0% | $253000 | — |
| Nov 13, 2023 | $-0.39 | $-0.38 | +2.6% | $419000 | -53.2% |
| Aug 10, 2023 | $-0.42 | $-0.35 | +16.7% | $915000 | +29.6% |
| May 12, 2023 | $-0.28 | $-0.40 | -42.9% | $1M | +71.2% |
| Jan 24, 2023 | $-0.43 | $-0.08 | +81.8% | $1M | +55.4% |
| Dec 16, 2022 | — | $-0.05 | — | $1M | — |
| Mar 31, 2022 | — | $-0.18 | — | $866000 | — |
OBIO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 28, 2026 | Sherman Darrendirector, officer: See Remarks | Tax | 4,925 | $5.26 |
| Aug 28, 2026 | Sherman Darrendirector, officer: See Remarks | Buy | 2,000 | $5.33 |
| Aug 28, 2026 | Aiello Joshuaofficer: Principal Accounting Officer | Tax | 203 | $5.26 |
| Aug 28, 2026 | Taylor Andrew Lawrenceofficer: Chief Financial Officer | Tax | 3,076 | $5.26 |
| Aug 14, 2026 | Fain Eric Sdirector | Tax | 5,145 | $4.42 |
| Aug 14, 2026 | Mack John Prosperdirector | Tax | 4,885 | $4.42 |
| Aug 14, 2026 | Cleary Chrisdirector | Tax | 4,238 | $4.42 |
| Aug 14, 2026 | Pacitti Daviddirector | Tax | 3,761 | $4.42 |
| Aug 4, 2026 | Sherman Darrendirector, officer: See Remarks | Sell | 15,000 | $4.09 |
| Jul 2, 2026 | Sherman Darrendirector, officer: See Remarks | Sell | 15,000 | $4.27 |
| Jun 25, 2026 | Pacitti Daviddirector | Grant | 21,277 | $4.04 |
| Jun 25, 2026 | Cleary Chrisdirector | Tax | 3,510 | — |
| Jun 25, 2026 | Cleary Chrisdirector | Grant | 42,553 | $4.04 |
| Jun 25, 2026 | Connealy Pamela Anndirector | Grant | 17,327 | — |
| Jun 25, 2026 | Connealy Pamela Anndirector | Grant | 21,277 | $4.04 |
Source: OBIO SEC Form 4 filings, latest Aug 28, 2026. For informational purposes only — not investment advice.
See the full OBIO insider & 13F page →Orchestra BioMed Holdings, Inc. company profile
Overview
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) is a biomedical innovation company founded in 2020 and based in New Hope, Pennsylvania. The company went public on August 4, 2020, and operates as a development-stage biotechnology firm focused on creating medical devices and therapies for cardiovascular and other critical health conditions. Orchestra BioMed has established strategic partnerships with major medical device companies including Medtronic and Terumo Corporation to advance its product pipeline through clinical development and eventual commercialization.
Business
Orchestra BioMed operates in the medical device and biotechnology sector, developing innovative solutions for cardiovascular diseases and minimally invasive surgical procedures. The company's business spans three primary product areas that address significant unmet medical needs. The flagship product candidate is BackBeat Cardiac Neuromodulation Therapy (CNT), a novel treatment approach for hypertension (high blood pressure). This therapy works by using electrical stimulation to modulate the nervous system's control of blood pressure, specifically targeting patients who already require cardiac pacemakers. Hypertension affects over one billion people worldwide and is a leading cause of heart disease, stroke, and kidney failure. Traditional treatments rely on medications, but BackBeat offers a device-based approach that could provide more consistent blood pressure control. The second major product is Virtue Sirolimus AngioInfusion Balloon (SAB), designed to treat atherosclerotic artery disease. Atherosclerosis occurs when arteries become narrowed and hardened due to plaque buildup, restricting blood flow and potentially causing heart attacks or strokes. The Virtue SAB is a specialized balloon catheter that delivers the drug sirolimus directly to the artery wall during angioplasty procedures. Sirolimus helps prevent the artery from re-narrowing (restenosis) after the procedure, improving long-term outcomes for patients. The third product line consists of FreeHold retractors, which are minimally invasive surgical devices used to hold tissues and organs in position during various surgical procedures. These devices enable surgeons to perform operations through smaller incisions, reducing patient trauma, recovery time, and complications compared to traditional open surgery approaches. Based on the company's limited revenue of approximately $2.6 million in 2024, all products appear to be in early commercial or late development stages, with revenue likely coming from development milestones, licensing agreements, or limited initial sales rather than full commercial distribution.
Revenue model
Orchestra BioMed's business model is primarily based on product development partnerships, licensing agreements, and eventual product sales, though the company is still in the pre-commercial stage for most of its offerings. The company generates revenue through several channels, including development milestone payments from strategic partners, licensing fees, and limited early-stage product sales. The company's two major strategic partnerships form the core of its revenue strategy. The collaboration with Medtronic, a global leader in medical technology, covers the development and commercialization of BackBeat CNT for treating hypertension in pacemaker patients. The partnership with Terumo Corporation, a major Japanese medical device company, focuses on developing and commercializing the Virtue SAB for artery disease treatment. These partnerships typically involve upfront payments, development milestone payments, and future royalties on commercial sales. Several factors could significantly impact Orchestra BioMed's margins and profitability. Positive factors include successful clinical trial outcomes that would trigger milestone payments and increase the likelihood of regulatory approval, leading to higher-margin royalty income. The company's partnerships with established medical device companies provide access to global distribution networks and reduce commercialization costs. Additionally, the large addressable markets for hypertension and cardiovascular disease treatments offer substantial revenue potential. Negative factors include the high costs and risks associated with clinical trials and regulatory approval processes, which can consume significant cash resources without guaranteed returns. Competition from established pharmaceutical and medical device companies with greater resources could limit market share. Regulatory delays or failures could eliminate revenue streams entirely. The company's dependence on partner companies for commercialization also means it has limited control over go-to-market strategies and pricing decisions. Manufacturing scale-up costs and quality control requirements for medical devices also present margin pressures as products move toward commercial launch.
Competitive moat
Orchestra BioMed's competitive moat is relatively narrow, which is typical for early-stage biotechnology companies. The company's primary defensive advantages stem from its intellectual property portfolio and strategic partnerships rather than established market positions or network effects. The company's intellectual property around its BackBeat CNT and Virtue SAB technologies provides some protection, but patents in the medical device space can be circumvented through alternative approaches or may face challenges from competitors with deeper resources for patent litigation. The specialized nature of cardiac neuromodulation therapy and drug-eluting balloon technologies does create some technical barriers to entry, as developing similar products requires significant expertise and clinical validation. The strategic partnerships with Medtronic and Terumo provide a form of competitive protection by aligning Orchestra BioMed with established industry leaders who have strong incentives to support the success of these products. These partnerships also provide access to regulatory expertise, clinical trial infrastructure, and global distribution networks that would be extremely expensive for Orchestra BioMed to develop independently. However, the company faces significant competitive threats. Large medical device companies like Medtronic, Abbott, Boston Scientific, and pharmaceutical giants have substantially greater resources for research and development, clinical trials, and regulatory processes. These companies could develop competing technologies or acquire smaller competitors. The medical device industry also has a history of rapid technological advancement, where breakthrough innovations can quickly obsolete existing approaches. The company's moat is currently weak to moderate, primarily dependent on execution risk and the success of its clinical programs. Without successful commercialization and market establishment, Orchestra BioMed remains vulnerable to well-funded competitors and faces the typical high failure rates associated with medical device development.
Risks & safety
Orchestra BioMed presents significant financial risks typical of pre-revenue biotechnology companies, with limited margin of safety for investors. **Cash Burn and Solvency Risk:** • Current cash position of $18.3 million as of Q1 2025, down from $22.3 million in Q4 2024 • Quarterly cash burn rate of approximately $16-17 million based on operating cash flow • At current burn rate, the company has roughly 4-5 quarters of cash runway remaining • Free cash flow of -$50.8 million for full year 2024 indicates substantial ongoing funding needs • Debt-to-equity ratio of 0.12 indicates low debt burden, but this also means limited debt financing options **Valuation Metrics:** • Current ratio of 3.35 provides some short-term liquidity cushion • Price-to-book ratio of 9.7 suggests high valuation relative to tangible assets • Negative earnings and EBITDA make traditional valuation metrics inapplicable • Market cap of approximately $127 million against minimal revenue indicates high speculative premium **Other Considerations:** • Graham net-net ratio of 0.20 indicates stock trades well above liquidation value • No meaningful revenue base to support current valuation • High dependence on clinical trial success and partnership milestone payments • Typical biotech binary risk profile where regulatory failure could eliminate most value
Recent development
Based on the available financial data, Orchestra BioMed has been focusing its development efforts on advancing its three core product lines through clinical trials and regulatory processes, though specific recent strategic developments are limited due to the absence of recent earnings call transcripts. The company's revenue has remained relatively stable but minimal, ranging from $2.6 million to $3.5 million annually between 2022-2024, suggesting the products are still in development phases rather than commercial launch. The slight decline in revenue from $3.5 million in 2022 to $2.6 million in 2024 may indicate a shift from early development milestone payments to a focus on later-stage clinical activities. The company's cash position has declined significantly from over $30 million in 2023 to $18.3 million in Q1 2025, indicating accelerated spending on development activities. This increased cash burn likely reflects advancement of clinical trials for both the BackBeat CNT and Virtue SAB products, as late-stage clinical trials typically require substantial investment in patient recruitment, clinical sites, and regulatory preparation. The strategic partnerships with Medtronic and Terumo appear to remain active, as evidenced by the continued modest revenue stream, likely from milestone payments and collaborative development funding. The company's focus appears to be on executing clinical development plans to achieve key regulatory milestones that would trigger additional partnership payments and move the products closer to commercial launch. The FreeHold retractor business appears to be generating some commercial revenue, though at modest levels, suggesting either limited market penetration or a focus on specific niche applications while the company prioritizes its higher-potential cardiovascular products.
OBIO company profile · for informational purposes only — not investment advice.
Track OBIO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free